The reported statements, read against the company's own industry.
Financials view
Market Capitalization
716.27MEUR
801.73M · vs all stocks (USD)
Updated Oct 25, 2026
Trailing P/E
101.20x
vs Biotechnology peers
Updated Oct 25, 2026
Revenue (TTM)
327.13MUSD
366.16M · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
2.54%
vs Biotechnology peers
Updated Oct 25, 2026
Beta
0.0740x
vs all stocks
Updated Oct 25, 2026
52-Week Change
-12.53%
vs all stocks
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
716.27MEUR
801.73M · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
599.22MEUR
670.71M · vs all stocks (USD)
Updated Oct 25, 2026
Trailing P/E
101.20x
vs Biotechnology peers
Updated Oct 25, 2026
Forward P/E
38.02x
vs Biotechnology peers
Updated Oct 25, 2026
Price to Sales (TTM)
1.95x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 2.19×.Updated Oct 25, 2026
Price to Book (MRQ)
2.98x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to Revenue
1.83x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to EBITDA
20.42x
vs Biotechnology peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 14.05×.Updated Oct 25, 2026
Gross Margin
83.88%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 86.52%.Updated Oct 25, 2026
Profit Margin
2.54%
vs Biotechnology peers
Updated Oct 25, 2026
Operating Margin
1.46%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Assets (TTM)
3.47%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Equity (TTM)
3.65%
vs Biotechnology peers
Updated Oct 25, 2026
Revenue (TTM)
327.13MUSD
366.16M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
0.5220USDUpdated Oct 25, 2026
Quarterly Revenue Growth
-3.20%
vs Biotechnology peers
Updated Oct 25, 2026
Gross Profit (TTM)
283.04MUSD
316.81M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
42.65MUSD
47.74M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
8.30MUSD
9.29M · vs all stocks (USD)
Updated Oct 25, 2026
Quarterly Earnings Growth (YoY)
-65.10%
vs Biotechnology peers
Updated Oct 25, 2026
Operating Cash Flow (TTM)
31.27MUSD
35.00M · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
33.64MUSD
37.65M · vs all stocks (USD)
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Trailing Annual Dividend Rate
0.00EURUpdated Oct 25, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 25, 2026
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025
Revenue
376.13MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
45.50MUSDFY2025 · Dec 31, 2025
Gross Profit
330.63MUSDFY2025 · Dec 31, 2025
Operating Income
20.88MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
12.85MUSDFY2025 · Dec 31, 2025
Income Tax Expense
10.31MUSDFY2025 · Dec 31, 2025
Net Income
2.54MUSDFY2025 · Dec 31, 2025
EBIT
23.57MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
36.28MUSDFY2025 · Dec 31, 2025
Research & Development
100.37MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
117.44MUSDFY2025 · Dec 31, 2025
Other Operating Expenses
82.74MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
2.18MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
10.72MUSDFY2025 · Dec 31, 2025
EPS (Basic)
0.0040USDFY2025 · Dec 31, 2025
EPS (Diluted)
0.0040USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
712.75MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
712.75MSharesFY2025 · Dec 31, 2025
Minority Interests (P&L)
313.00KUSDFY2025 · Dec 31, 2025
Operating Cash Flow
47.47MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
145.31MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
12.85MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
11.22MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
13.77MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
13.38MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-3.35MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-386.00KUSDFY2025 · Dec 31, 2025
Net Intangibles (CF)
-6.00KUSDFY2025 · Dec 31, 2025
Net Acquisitions
-58.22MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-2.00KUSDFY2025 · Dec 31, 2025
Sale of Investments
85.22MUSDFY2025 · Dec 31, 2025
Other Investing Activity
-1.00KUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
27.01MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025
Long-term Debt Payments
-4.25MUSDFY2025 · Dec 31, 2025
Common Dividends Paid
0.00USDFY2025 · Dec 31, 2025
Other Financing Charges
-7.88MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-12.12MUSDFY2025 · Dec 31, 2025
Shares Outstanding
707.78MSharesUpdated Oct 25, 2026
Float Shares
696.57MSharesUpdated Oct 25, 2026
% Held by Insiders
0.99%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
22.97%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
141.29MUSD
158.15M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
0.2240USDUpdated Oct 25, 2026
Total Debt (MRQ)
101.13MUSD
113.20M · vs all stocks (USD)
Updated Oct 25, 2026
Total Debt to Equity (MRQ)
0.4189x
vs Biotechnology peers
Updated Oct 25, 2026
Current Ratio (MRQ)
3.01x
vs Biotechnology peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
0.3400USDUpdated Oct 25, 2026
Total Assets
499.96MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
299.47MUSDFY2025 · Dec 31, 2025
Total Liabilities
222.86MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
200.50MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
107.07MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
115.79MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
145.31MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
33.80MUSDFY2025 · Dec 31, 2025
Accounts Receivable
41.77MUSDFY2025 · Dec 31, 2025
Inventory
64.90MUSDFY2025 · Dec 31, 2025
Accounts Payable
8.54MUSDFY2025 · Dec 31, 2025
Short-term Debt
8.71MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
-1.00KUSDFY2025 · Dec 31, 2025
Long-term Debt
107.07MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
8.01MUSDFY2025 · Dec 31, 2025
Retained Earnings
-272.98MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
277.10MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
0.8200EURUpdated Oct 25, 2026
52-Week High
1.82EURUpdated Oct 25, 2026
52-Week Change
-12.53%
vs all stocks
Updated Oct 25, 2026
Beta
0.0740x
vs all stocks
Updated Oct 25, 2026
50-Day MA
0.9300EURUpdated Oct 25, 2026
200-Day MA
1.19EURUpdated Oct 25, 2026
Avg 10-Day Volume
8.47MSharesUpdated Oct 25, 2026
Avg 30-Day Volume
7.97MSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
0.0100USDUpdated Oct 25, 2026
Other Income / Expense
704.00KUSDFY2025 · Dec 31, 2025
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.84Profit Margin: 0.03
Financial Health
Altman Z-Score 2.7: safe zoneNotable
Altman Z-Score: 2.70
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $37.65M, above the global median of $18.58MNotable